Bevacizumab for Neovascular Age-related Macular Degeneration
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
Age-related macular degeneration (AMD) is one of primary blinding eye disease among people
over 65 years in China. The anti-VEGF antibody treatment is proved useful for Neovascular
Age-related Macular Degeneration (nAMD) by many studies. Bevacizumab is the only available
low-cost type of anti-VEGF drug currently in China. This study is a multi-center, randomized
trial of Bevacizumab effective dose and safety for nAMD. This study is to explore the
effective therapeutic approach that the majority of patients in China can bear establishing a
suitable treatment for China.